TAINAN, June 12, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzheimer's disease (AD). TML-6 combines multiple mechanisms, including anti-oxidative effects...
Read More Details
Finally We wish PressBee provided you with enough information of ( Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer's Disease )
Also on site :
- Global March to Gaza activists report delays, deportations at Cairo Airport
- Egypt sets strict protocols for Gaza border access amid the Soumoud Convoy arrival
- She helped build Disney’s theme park database. Now Sheila Jordan is leading a $38.5 billion Fortune 500 giant’s digital transformation efforts